Veeda UK awarded the MHRA Phase I Supplementary Accreditation
Veeda UK today announced that it is been awarded Supplementary accreditation for conducting clinical pharmacology Phase I Trials in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA)
The Accreditation Scheme was introduced in 2008 following the review of the TGN-1412 incident and provides formal guidance on the standards expected in a unit conducting First In Human Trials. There are two levels of assessment – Standard which shows the company as competent to perform most Phase I studies and Supplementary which indicates the centre has demonstrated they have the necessary experience, robust systems in place and highest standards maintained for the conduct of FIH trials and in particular those involving drugs that would require risk review from the EAG (Expert Advisory Group)
In order to be awarded Supplementary level accreditation the Phase I Units concerned have to undergo stringent inspection by the MHRA with a particular emphasis on investigator competence and the implement of all safety procedures.
The voluntary accreditation process provides clinical trial volunteers and sponsors with additional reassurance and confidence that the Veeda Phase I Unit meets the very highest of industry safety standards. The award further confirms the quality standards that Veeda delivers and enables the unit to continue to carry out clinical trials at all levels of complexity Dr Maurice Cross, Group Medical Director said
After the tragic outcome of the study carried out at the Northwick Park Unit in London, the UK MHRA introduced stringent new standards for Phase I Units wishing to perform First-into-Man studies of those new molecules which are classed as being 'high risk'. Units which successfully pass this accreditation scheme are increasingly being chosen as the places of choice to perform these studies in preference to non-accredited units as the ‘comfort-factor’ for clients substantially increases.It is much to the credit of the Plymouth Unit and its staff that we have become included in this elite group.
For further information, please contact:
Priyanka Shah
Tel: +91 9879068886
priyanka.shah@veedacr.com
Press Contact:
Priyanka Shah
Veeda Clinical Research® - India
Shivalik Plaza-A, Near IIM
Ambawadi
Ahmedabad- 380 015
India
+91 79 3001 3000
http://www.veedacr.com
**e**.**@**a**.com
Email partially hidden to block spam. Please use the contact form here.
More User Press Releases
- Veeda Oncology Announces $8.4 million in New Business
- Apurva Shah selected as the new chairman of ACRO
- Veeda Clinical Research demonstrates its Potential in Experimental Medicine
- Veeda represented at Prime Ministers Meeting
- Veeda celebrates 5 years of success
- Veeda announces the appointment of Mr. Venu Madhav as the new COO
- The BioEntrepreneur Award for emerging as a Global CRO – Veeda Clinical research
- Veeda Clears ANVISA Inspection for the 4th Consecutive Time
- Co-development of drugs in the East and West
Like this site on Facebook
Distribute Press Release
- Post press release to 50+ free press release websites.
- Send to 100+ online publications.
- Effortlessly publish all your press releases with our automated pickup and submission service.
User login
Search
Bookmark/Search this post
Primary Menu
- News by Region
- Business
- List of Industries
- Technology
- Aerospace & Defense
- Agriculture & Forestry
- Arts
- Automotive
- Business Services
- Chemicals
- Construction & Maintenance
- Consumer Goods
- Education
- Electrical & Electronics
- Energy
- Entertainment
- Food & Related Products
- General Business
- Government
- Healthcare
- Heavy Industry
- Home
- Industrial Goods & Services
- Industrial Materials
- Medical
- Mining & Drilling
- Publishing & Printing
- Retail
- Society
- Sports
- Supermarkets
- Telecommunications
- Textiles & Nonwovens
- Transportation & Logistics
- Travel & Hospitality
- Wholesale
